Work and Cost Burden Reported by 220 Swedish Adults With Atopic Dermatitis
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured scene is an AI-created illustration of a fictional work, home or research setting. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
The question behind this paper
This review looks at household finances, presenteeism and activity impairment. The aim is to preserve the study’s actual population, denominator, design and timepoint so a useful signal does not become a universal claim.
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 220 adult members of the Swedish Asthma and Allergy Patient Association with self-reported current or previous AD |
| Design | Cross-sectional online patient-reported-outcomes survey |
| Timepoint | January 2024 to January 2025, with one-month recall and modeled annual costs |
| Key result | Mean DLQI was 10.1. Among employed respondents, overall work impairment averaged 26.6%, presenteeism 24.6% and absenteeism 4.3%; mean annual out-of-pocket cost was €900 and modeled productivity loss €1,972. |
How to interpret the result
The study captures costs and work effects that disease-severity scores can miss. Its euro estimates are context-specific modeled values, not universal annual costs for every person with AD.
Important limitation: Participants were 89.8% female and self-selected from a patient association, AD and severity were self-reported, and annualization applies only to symptom-active periods.
Questionnaires, examinations, sensors, patch tests and administrative records answer different questions. A screening or monitoring result can guide the next step, but it does not diagnose the cause of one person’s rash. An association can identify a pattern worth investigating without proving that a single task, material or personal factor caused every event.
Questions a worker, family or clinician can ask next
- What exactly was measured: reported symptoms, visible signs, allergy, work loss or quality of life?
- Which denominator applies to the quoted percentage: everyone invited, respondents, symptomatic people, examined participants or a selectively tested subgroup?
- Did the study compare groups or follow change over time, and what factors could still explain the difference?
- Would clinician examination, occupational-health review or clinician-directed testing change the practical plan?
- What requires prompt medical evaluation, including rapidly spreading redness, drainage, fever, severe pain, breathing symptoms or major loss of function?
Primary and authoritative sources
- Primary medical research record: PubMed PMID 41841275
- Authoritative guidance relevant to this topic
- American Academy of Dermatology: eczema skin-care guidance
PubMed indexing is not NIH endorsement of a study’s interpretation, this article or any product.
Where a cosmetic moisturizer fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and outside research does not become a product result. #003 is not an eczema medicine and this article makes no treatment, cure, prevention, pediatric-safety or 24-hour claim.
Bottom line
The responsible conclusion is narrow: keep the population, denominator, comparator, timepoint and limitations attached, then use the evidence to ask better clinical and exposure-control questions rather than promise a universal result.